All the news Showing 10 of 10 articles from: Pan-genotypic regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources FDA approves first treatment for all genotypes of hepatitis C in pediatric patients Food & Drug Administration / 02 May 2019 New treatment could see NZ eradicate Hepatitis C in next 20 years Newshub / 17 December 2018 The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir Medicines Patent Pool / 12 November 2018 China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection Gilead press release / 30 May 2018 NICE nod for Gilead’s pan-genotypic hepatitis C therapy PharmaTimes / 21 February 2018 New three-drug HCV regimen shows nearly 100% response in 6, 8 weeks Healio Hepatology / 30 October 2017 European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C Gilead press release / 31 July 2017 European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie press release / 31 July 2017 FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes HIVandHepatitis.com / 04 July 2016 Washington Ordered to Cover Hepatitis C Drugs During Lawsuit Bloomberg / 31 May 2016 ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive